Last news
Anamana Incubator Targets Culturally Native Creators to Diversify Homogenized Micro-Drama Market

Anamana Incubator Targets Culturally Native Creators to Diversify Homogenized Micro-Drama Market

AI-native micro-serial platform invests in culture-driven stories made by insiders to differentiate from global ROI-driven legacy platforms SINGAPORE, June 8, 2026 /PRNewswire/ -- Anamana, the platform for AI-native micro-serials, is using its...

Uhale Adopts Quokka's Q-mast to Strengthen Application Security Testing

Uhale Adopts Quokka's Q-mast to Strengthen Application Security Testing

Integration of automated security testing solution supports Uhale's ongoing efforts to enhance user protection SINGAPORE, June 8, 2026 /PRNewswire/ -- Uhale, the software provider for digital photo frames, today announced that it has adopted...

Novonesis showcases biosolutions for Korean food producers at Seoul Food & Hotel 2026

Novonesis showcases biosolutions for Korean food producers at Seoul Food & Hotel 2026

Novonesis, a global biosolutions leader, will demonstrate how biosolutions can support more efficient food production while enhancing taste, texture, and nutritional quality that can provide benefits to Korean consumers. SEOUL, South Korea, June 8,...

Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize LNZ100 in Greater China

Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize LNZ100 in Greater China

SHANGHAI, June 8, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today...

Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program

Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program

SAN DIEGO, June 8, 2026 /PRNewswire/ -- Sapu Bioscience LLC announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for Injection) and the appointment of Global Clinical Trials (GCT) as the lead contract research...

Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39

Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39

HONG KONG, June 8, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes Association (ADA) 2026 Scientific Sessions (taking place June 5-8, 2026, in New Orleans,...

OriCell's GPC3 CAR-T Receives NMPA Clearance for Confirmatory Phase II Trial in Late-Line Advanced Hepatocellular Carcinoma

OriCell's GPC3 CAR-T Receives NMPA Clearance for Confirmatory Phase II Trial in Late-Line Advanced Hepatocellular Carcinoma

SHANGHAI, June 8, 2026 /PRNewswire/ -- OriCell Therapeutics Holdings Limited ( The "Company" or "Oricell") , announced that its proprietary GPC3-targeted autologous CAR-T therapy, Ori-C101, has received clearance from China's National Medical...

Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance

Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance

SHANGHAI and HONG KONG, June 8, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class...

1 ... 8 9 10 11 12 13 14 15 16 ... 4717
menu
menu